Royce & Associates’s Cardlytics CDLX Stock Holding History

Royce & Associates’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,400	Closed	-$980K	–	1021
2020 Q2	$980K	Buy	+1,400	New	+$808K	0.01%	786

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Royce & Associates's CDLX Position: Q3 2020 in Review

Royce & Associates sold out of Cardlytics (CDLX) in Q3 2020, closing a stake of 1,400 shares — an estimated $980K sold.

Royce & Associates first reported a position in CDLX in Q2 2020 and held it in 1 quarter. The position peaked at $980K in Q2 2020. 164 funds tracked by Wall St. Rank hold CDLX as of Q3 2020.

Royce & Associates reported no remaining Cardlytics position as of Q3 2020 after selling out during the quarter.
Royce & Associates sold 1,400 Cardlytics shares in Q3 2020, an estimated $980K.
Royce & Associates first reported a position in Cardlytics in Q2 2020 and held it in 1 quarter.
Royce & Associates's Cardlytics position peaked at $980K in Q2 2020.
164 funds tracked by Wall St. Rank held Cardlytics as of Q3 2020.

Based on Royce & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.